(Alliance News) - Hutchmed (China) Ltd - Hong-Kong based pharmaceutical company - Starts phase two trial of cancer treatment Orpathys, whose generic name is savolitinib. First dose administered on Tuesday. Hutchmed in partnership with AstraZeneca PLC and Beijing Cancer Hospital to conduct the trial. This follows multiple gastric cancer - cancer formed in the lining of the stomach - studies. Trial will probe the effectiveness of Orpathys in sufferers of advanced or metastatic MET amplified gastric cancer or adenocarcinoma of the gastroesophageal junction, cancer of the oesophagus which connects a body's mouth to the stomach. Metastatic cancer refers to when the disease spreads to other parts of the body.
Current stock price: 575.00 pence, up 7.1% on Wednesday
Year-to-date change: up 25%
By Josie O'Brien; josieobrien@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
Astrazeneca (AZN)
Hutchmed (HCM)